Table 2.

Timeline

Date	Event	Comment
December 2012	Marketing authorisation AA extended to pre-docetaxel
April 2014	ACM 1	ACD 1: not recommended (AC concluded that all the ICERs estimated by both the company and the ERG fell substantially above the range normally considered cost effective, i.e. £20,000–30,000 per QALY gained)
June 2014	ERG addendum 1	ERG response to comments raised during ACD consultation on the benefit of delaying chemotherapy
June 2014	ACM 2	FAD 1: not recommended (AC concluded that all the ICERs estimated by both the company and the ERG fell substantially above the range normally considered cost effective, i.e. £20,000–30,000 per QALY gained)
September 2014	Appraisal suspended pending revised PAS
April 2015	ERG addendum 2	ERG response to new PAS
October 2015	ACM 3	Request new data from company
November 2015	ERG addendum 3	ERG response to the company’s response to NICE’s request for additional information
November 2015	ACM 4	ACD 2: not recommended (AC most plausible ICER likely between £35,500 and £59,600 per QALY gained)
January 2016	ERG addendum 4	ERG response to the company’s response to ACD
February 2016	ACM 5	FAD 2: recommended (AC most plausible ICER likely between £28,600 and £32,800 per QALY gained; see Sect. 5)

AA abiraterone acetate, ACM Appraisal Committee Meeting, ACD Appraisal Consultation Document, AC Appraisal Committee, ICER incremental cost-effectiveness ratio, ERG Evidence Review Group, QALY quality-adjusted life-year, PAS patient access scheme, FAD Final Appraisal Determination, NICE National Institute for Health and Care Excellence